)
Visual
earnings real time
Senti Biosciences (SNTI) investor relations material
Senti Biosciences Study Update summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Study Update summary9 Dec, 2025
Study background and rationale
Senti 202/SENTI-202 is a first-in-class, off-the-shelf logic-gated CAR-NK cell therapy targeting CD33 or FLT3 with a NOT gate for endomucin, designed to selectively kill AML cells while sparing healthy cells.
The therapy addresses the challenge of finding clean targets in AML by using logic gates to enhance selectivity and reduce toxicity.
Senti 202 includes a calibrated release IL-15 to boost NK cell and host immune activity.
The product is manufactured from healthy adult donor NK cells, enabling rapid, scalable, allogeneic, off-the-shelf delivery.
The addressable market is broad, with potential expansion into newly diagnosed AML, pediatric AML, and myelodysplastic syndrome.
Clinical trial design and patient population
Phase 1, open-label, multinational, multicenter trial enrolled 20 heavily pretreated relapsed/refractory AML or MDS patients, including those with adverse risk genetics and poor prognosis.
Dose finding followed by expansion at the recommended phase 2 dose (RP2D) of 1.5 x 10⁹ CAR+ NK cells.
Patients had a median of 2 prior lines of therapy, with high rates of prior HCT and refractory disease.
Median age was 49, with most patients having received multiple prior lines of therapy, including chemotherapy and targeted agents.
The RP2D cohort had more heavily pretreated and refractory patients compared to dose level one.
Efficacy results
50% overall response rate (ORR) and 42% CR/CRh rate at RP2D in relapsed/refractory AML patients.
All complete remissions (CR) were MRD negative, with MRD negativity rates exceeding 80% across all response types.
Responses were rapid (median time to response 1.2 months) and durable, with estimated median duration of composite CR at 7.6 months; some responses lasted over a year.
Responses observed across diverse patient subgroups, including those with adverse risk genetics and prior refractory disease.
Efficacy was independent of FLT3 mutation status, benefiting both wild-type and mutant patients.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Senti Biosciences earnings date
Q4 202520 Mar, 2026
Next Senti Biosciences earnings date
Q4 202520 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Senti Biosciences Inc. is a biotechnology company engaged in developing innovative cell and gene therapies. The company specializes in the use of gene circuit technologies, which involve designing and programming cells to function as intelligent medicines capable of addressing various diseases. Senti Biosciences’ platform focuses on three main areas: off-the-shelf CAR-NK cells for oncology, gene therapies targeting specific tissues, and cell therapies for regenerative medicine. Their lead product candidates include therapies targeting different types of cancer using CAR-NK cells engineered with these gene circuits. Senti Biosciences is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage